OUR SCIENTIFIC PUBLICATIONS
The technology platforms at Ios Biomedical Group are grounded in over three decades of peer-reviewed virology and immunology research. Our proprietary HSV-1 vectors and computational discovery engines have been validated in rigorous preclinical studies, demonstrating superior safety profiles, robust immunogenicity, and efficacy against difficult-to-treat cancers and infectious diseases. Below is a selection of key publications authored by our scientific leadership and collaborators.
ViraVacG™: The Oncology Platform
Our lead oncology candidate, ViraVacG™, is an oncolytic virus engineered to selectively replicate in tumor cells while sparing healthy tissue. The papers below validate its unique design—specifically the expression of GM-CSF—which recruits the patient’s own immune system to attack the tumor. This research demonstrates efficacy in “cold” tumors like pancreatic cancer and triple-negative breast cancer, as well as the ability to induce a systemic “abscopal” effect that targets metastasis.
Validating ViraVacG™ in Metastatic Breast Cancer
The Novel Oncolytic Herpes Simplex Virus Type-1 (HSV-1) Vaccine Strain VC2 Constitutively Expressing GM-CSF Causes Increased Intratumoral T Cell Infiltration and Inhibition of Tumor Metastasis in the 4T1/Balb/c Mouse Model of Stage Four Breast Cancer.
ViraVac™: The Vaccine Platform
Safety is the primary barrier to HSV vaccine development. The ViraVac™ (VC2) platform solves this through specific genetic deletions that prevent the virus from entering neurons and establishing latency. The research below validates that ViraVac™ is not only safe (non-neurotropic) but also highly effective, offering cross-protection against both HSV-1 and HSV-2, and preventing severe complications like herpetic blindness.
AI-Driven Phytochemical Discovery
IBG utilizes advanced artificial intelligence and Large Language Models (LLMs) to accelerate drug discovery. We utilize systems like “CancerOmicsNet” to predict how natural compounds interact with cancer cell signaling pathways. The publications below highlight our move from in silico (computational) predictions to precision oncology and dermatological formulations.
Mechanism of Action (Virology)
Understanding the molecular mechanics of the HSV-1 virus is central to our engineering strategy. These foundational papers describe the specific functions of the glycoprotein K (gK) and UL20 proteins. This research explains the biological mechanism that allows us to disable the virus’s ability to hide in the nervous system while enhancing its ability to replicate for manufacturing purposes.
